Cost and cost-effectiveness of three strategies for implementing motivational interviewing for substance misuse on medical inpatient units.


Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 02 01 2020
revised: 22 06 2020
accepted: 24 06 2020
pubmed: 14 7 2020
medline: 17 3 2021
entrez: 14 7 2020
Statut: ppublish

Résumé

This study conducted cost and cost-effectiveness analyses of three strategies for implementing motivational interviewing for substance misuse on general medical inpatient units: workshop, apprenticeship, and consult. The economic analyses were conducted prospectively alongside a type 3 hybrid effectiveness-implementation randomized trial comprising 38 medical providers, 1173 inpatients, and four consultation-liaison motivational interviewing experts. The trial took place in a university affiliated teaching hospital in New Haven, CT, USA. After completing a 1-day workshop on motivational interviewing, providers were randomized to conditions. The primary outcome measure was the number of study-eligible patients who received a motivational interview. The economic analyses included the costs of both start-up and on-going activities in each condition. Incremental cost-effectiveness ratios were used to determine cost effectiveness. Results are presented from the healthcare provider (i.e., hospital) perspective in 2018 US dollars. The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively. Workshop and apprenticeship were extended dominated by the combination of consult and doing nothing. Doing nothing is cost effective when the willingness-to-pay for an additional patient receiving a motivational interview is less than $185.65, and consult is cost-effective when the willingness-to-pay for an additional patient receiving a motivational interview is greater than $185.65. Given that typical reimbursements for brief intervention services for substance misuse are $35-$65, none of the three implementation strategies is likely to be economically viable from the healthcare provider perspective.

Sections du résumé

BACKGROUND
This study conducted cost and cost-effectiveness analyses of three strategies for implementing motivational interviewing for substance misuse on general medical inpatient units: workshop, apprenticeship, and consult.
METHODS
The economic analyses were conducted prospectively alongside a type 3 hybrid effectiveness-implementation randomized trial comprising 38 medical providers, 1173 inpatients, and four consultation-liaison motivational interviewing experts. The trial took place in a university affiliated teaching hospital in New Haven, CT, USA. After completing a 1-day workshop on motivational interviewing, providers were randomized to conditions. The primary outcome measure was the number of study-eligible patients who received a motivational interview. The economic analyses included the costs of both start-up and on-going activities in each condition. Incremental cost-effectiveness ratios were used to determine cost effectiveness. Results are presented from the healthcare provider (i.e., hospital) perspective in 2018 US dollars.
RESULTS
The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively. Workshop and apprenticeship were extended dominated by the combination of consult and doing nothing. Doing nothing is cost effective when the willingness-to-pay for an additional patient receiving a motivational interview is less than $185.65, and consult is cost-effective when the willingness-to-pay for an additional patient receiving a motivational interview is greater than $185.65.
CONCLUSIONS
Given that typical reimbursements for brief intervention services for substance misuse are $35-$65, none of the three implementation strategies is likely to be economically viable from the healthcare provider perspective.

Identifiants

pubmed: 32659637
pii: S0376-8716(20)30321-5
doi: 10.1016/j.drugalcdep.2020.108156
pmc: PMC7448551
mid: NIHMS1608928
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

108156

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA034243
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they do not have a conflict of interest.

Références

Int Rev Psychiatry. 2018 Dec;30(6):292-309
pubmed: 30821540
Arch Intern Med. 2004 Apr 12;164(7):749-56
pubmed: 15078644
Subst Abuse Rehabil. 2014 Jul 01;5:63-73
pubmed: 25114610
Addiction. 2011 Feb;106(2):428-41
pubmed: 20925684
Addict Sci Clin Pract. 2017 Nov 17;12(1):32
pubmed: 29149909
Int J Med Inform. 2015 Dec;84(12):1057-64
pubmed: 26456569
Addiction. 2017 Feb;112 Suppl 2:65-72
pubmed: 28074563
Drug Alcohol Depend. 2005 Oct 1;80(1):105-16
pubmed: 16157233
J Gen Intern Med. 2020 Apr;35(4):1001-1010
pubmed: 31792866
J Hosp Med. 2008 Sep;3(5):369-75
pubmed: 18951399
J Subst Abuse. 1993;5(2):187-93
pubmed: 8104569
J Gen Intern Med. 2019 Nov;34(11):2520-2529
pubmed: 31468342
J Consult Clin Psychol. 2018 Feb;86(2):140-157
pubmed: 29265832
Addiction. 2014 Aug;109(8):1287-94
pubmed: 24661345
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Wis Med J. 1995;94(3):135-40
pubmed: 7778330
J Gen Intern Med. 2006 Apr;21(4):381-5
pubmed: 16686818
J Subst Abuse Treat. 2008 Jul;35(1):1-12
pubmed: 17935930
Br J Addict. 1989 Jul;84(7):791-9
pubmed: 2758152
J Subst Abuse Treat. 2016 Jan;60:54-61
pubmed: 26160162

Auteurs

Todd A Olmstead (TA)

The University of Texas at Austin, Lyndon B. Johnson School of Public Affairs, Sid Richardson Hall, Unit 3, Austin, TX, 78712, USA. Electronic address: tolmstead@austin.utexas.edu.

Kimberly A Yonkers (KA)

Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA; Yale School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, 333 Cedar Street, New Haven, CT, 06510, USA; Yale School of Epidemiology and Public Health Division of Chronic Disease, 60 College Street, New Haven, CT, 06520, USA.

Ariadna Forray (A)

Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.

Paula Zimbrean (P)

Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.

Kathryn Gilstad-Hayden (K)

Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.

Steve Martino (S)

Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA; VA Connecticut Healthcare System, Psychology Service, 950 Campbell Avenue (116B), West Haven, CT, 06516, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH